Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

BACKGROUND/AIMS: Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is sorafenib. However, adaptive resistance has been observed in HCC patients undergoing long-term soraf...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Mol Hepatol
Asıl Yazarlar: Makol, Ankita, Kaur, Harpreet, Sharma, Sakshi, Kanthaje, Shruthi, Kaur, Ramanpreet, Chakraborti, Anuradha
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The Korean Association for the Study of the Liver 2020
Konular:
Original Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6940489/
https://ncbi.nlm.nih.gov/pubmed/31564085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2019.0031
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller